Sugi Predict

Sugi Predict / Compounds / SCHEMBL173108

SCHEMBL173108

SCHEMBL173108

COC(=O)c1sc(C(C)(C)C)cc1N

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 13/20 0.56
▸ MAPK14 Q16539 8/20 0.56
▸ MAPK13 O15264 1/20 0.51
▸ MAPK12 P53778 1/20 0.51
▸ MAPK11 Q15759 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ CASP3 P42574 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SENP8 Q96LD8 1/20 0.50
▸ SENP7 Q9BQF6 1/20 0.50
▸ SENP6 Q9GZR1 1/20 0.50
▸ IKBKB O14920 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12949478 0.87 KDM4E (0.48) RAF1MAPK14MAPK13MAPK12MAPK11
Hydrochloric Acid SCHEMBL11007849 0.83 IKBKB (0.51) RAF1MAPK14KDM4ENPC1MAPT
SCHEMBL1883586 0.82 MAPT (0.56) RAF1MAPK14KDM4ENPC1MAPT
SCHEMBL161668 0.81 RAF1 (0.56) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL164073 0.80 IKBKB (0.46) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL14189999 0.80 RXFP1 (0.49) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL2063091 0.80 RXFP1 (0.41) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL3239031 0.80 KDM4E (0.54) KDM4ENPC1MAPTL3MBTL1CASP3
SCHEMBL1912421 0.79 RAF1 (0.51) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL10264809 0.79 L3MBTL1 (0.53) RAF1MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 — — US disclosed
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-03-23 — — US disclosed
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-03-23 — — US disclosed
EP-3048106-B1 THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2019-11-06 — — EP disclosed
EP-3048106-B1 THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2019-11-06 — — EP disclosed
US-20190106433-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C WINDTREE THERAPEUTICS, INC. 2019-04-11 — — US disclosed
US-20190106433-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C WINDTREE THERAPEUTICS, INC. 2019-04-11 — — US disclosed
US-10183950-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-01-22 — — US disclosed
US-10183950-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-01-22 — — US disclosed
US-20170158706-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-06-08 — — US disclosed
WO-2000055152-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-09-21 — — WO disclosed
EP-1019040-A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS Bayer Corporation (US) 2000-07-19 — — EP disclosed
EP-0986382-A1 RAF KINASE INHIBITORS Bayer Corporation (US) 2000-03-22 — — EP disclosed
WO-1999040091-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS AMGEN INC. (US) 1999-08-12 — — WO disclosed
WO-1999032110-A1 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 — — WO disclosed
WO-1999032106-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 — — WO disclosed
WO-1999032455-A1 INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 — — WO disclosed
WO-1999032111-A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 — — WO disclosed
WO-1998052558-A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS BAYER CORPORATION (US) 1998-11-26 — — WO disclosed
WO-1998052559-A1 RAF KINASE INHIBITORS BAYER CORPORATION (US) 1998-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183950-B2 Thienopyrimidine inhibitors of atypical protein kinase C PRKCQ, PRKDC, PRKACA RAF1 41/4885MAPK14 260/4885MAPK13 263/4885
US-20190106433-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C PRKX, PRKCQ, PRKACA RAF1 52/4885MAPK14 283/4885MAPK13 233/4885
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 RAF1 1875/4885MAPK14 1153/4885MAPK13 1391/4885
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C PRKX, PRKCQ, PRKACA RAF1 52/4885MAPK14 283/4885MAPK13 233/4885
US-20170158706-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C PRKCQ, PRKDC, PRKACA RAF1 41/4885MAPK14 260/4885MAPK13 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.